HSP90AA1 and leukemia: Notably, prior studies have demonstrated that chaetocin binds to the C-terminal domain of HSP90α in leukemia, disrupting the function of several HSP90 client proteins and subsequently activating the proteasome pathway to degrade SUV39H1 [33].